← Leaderboards
Matthew Louis Hirsch
Univ Of North Carolina Chapel Hill
$4,267,556
Attributed
$7,205,550
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,205,550 · 9
By mechanism
R01$3,470,137 · 2
R42$1,769,317 · 1
R41$1,520,098 · 5
R21$445,998 · 1
Top collaborators
- Richard J Samulski8 shared
- Brian C Gilger6 shared
- Nathaniel A. Hathaway2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Bruce A Cairns$5,721,017
- Brian Patrick Conlon$5,321,207
Others in their field
Top investigators on “Vector”
- Lawrence Corey · Fred Hutchinson Cancer Center$446,547,761
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$239,426,049
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$142,420,923
- David Heimbrook · Leidos Biomedical Research, Inc.$141,066,079
- Peter B. Gilbert · Fred Hutchinson Cancer Center$124,296,230
- Philip Goode · New Jersey Institute Of Technology$73,697,028
Research focus
VectorGene TherapyAdeno-Associated Viral VectorMediatingProteinsImmuneDoseEngineeringProductionTransgenesAnimal ModelImmune ResponseTechnologyPreventTissuesCellsCapsidBaseGenesGene Transduction AgentHereditary DiseaseMutantClinical TrialsPharmaceutical Preparations
Grant awards (20)
Prevention of corneal transplant rejection using AAV-BDRK-401 therapy$793,930
R42 · FY2025 · EY
Vector mediated anti-vascular and anti-inflammatory therapy for AMD$310,952
R41 · FY2025 · EY
Prevention of corneal transplant rejection using AAV-BDRK-401 therapy$975,387
R42 · FY2024 · EY
Chemically regulating AAV transgene expression with endogenous gene activators$194,375
R21 · FY2023 · AI · contact PI
Tolerability and Potency of Sequential and Repeated AAV Corneal Gene Therapy$367,624
R41 · FY2022 · EY · contact PI
Novel platform for optimizing AAV transgene expression to improve efficacy of ocular gene therapies$263,372
R41 · FY2022 · EY · contact PI
Chemically regulating AAV transgene expression with endogenous gene activators$251,623
R21 · FY2022 · AI · contact PI
Immunosuppressive Gene Therapy for Ocular Graft vs Host Disease$328,150
R41 · FY2021 · EY
Prevention of corneal transplant rejection using AAV-HLA-G combination therapy$171,923
R41 · FY2021 · EY
Prevention of corneal transplant rejection using AAV-HLA-G combination therapy$78,077
R41 · FY2020 · EY
Rational and Combinatorial Engineering of AAV Vectors$378,128
R01 · FY2017 · AI · contact PI
Overcoming our clinical complications: AAV vector design for the treatment of DMD$320,437
R01 · FY2017 · AR · contact PI
Rational and Combinatorial Engineering of AAV Vectors$378,128
R01 · FY2016 · AI · contact PI
Overcoming our clinical complications: AAV vector design for the treatment of DMD$320,437
R01 · FY2016 · AR · contact PI
Rational and Combinatorial Engineering of AAV Vectors$378,128
R01 · FY2015 · AI
Overcoming our clinical complications: AAV vector design for the treatment of DMD$320,437
R01 · FY2015 · AR · contact PI
Rational and Combinatorial Engineering of AAV Vectors$378,128
R01 · FY2014 · AI
Overcoming our clinical complications: AAV vector design for the treatment of DMD$320,437
R01 · FY2014 · AR
Rational and Combinatorial Engineering of AAV Vectors$355,440
R01 · FY2013 · AI
Overcoming our clinical complications: AAV vector design for the treatment of DMD$320,437
R01 · FY2013 · AR